Although these products are used less frequently than insulin, these annual out-of-pocket costs are on par with—and in some cases exceed—those associated with insulin,6 and may be unaffordable for the hundreds of thousands of older adults with diabetes and elevated cardiovascular risk who may receive clinical benefit from one of these newer agents. Here, INS is linked to diabetes mellitus.